Reminder of Class Action for Corcept Therapeutics Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy CORT?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, to apply as lead plaintiffs by April 21, 2026, to participate in the class action and seek compensation.
- No Cost Compensation: Participants can receive compensation through a contingency fee arrangement that requires no out-of-pocket expenses, thereby reducing the financial burden on investors and encouraging more affected shareholders to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Corcept made false statements regarding the efficacy of relacorilant in key clinical trials, leading investors to face significant risks during the FDA approval process, ultimately resulting in a stock price decline and investor losses.
- Law Firm Advantages: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 43.900
Low
50.00
Averages
91.00
High
121.00
Current: 43.900
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder of Class Action for Corcept Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, to apply as lead plaintiffs by April 21, 2026, to participate in the class action and seek compensation.
- No Cost Compensation: Participants can receive compensation through a contingency fee arrangement that requires no out-of-pocket expenses, thereby reducing the financial burden on investors and encouraging more affected shareholders to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Corcept made false statements regarding the efficacy of relacorilant in key clinical trials, leading investors to face significant risks during the FDA approval process, ultimately resulting in a stock price decline and investor losses.
- Law Firm Advantages: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds Corcept Therapeutics shareholders that April 21, 2026, is the critical deadline to apply as lead plaintiff, urging investors to submit their losses before this date.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant flaws in its communications with the FDA regarding its lead drug candidate, relacorilant, misleading investors about the drug's approval prospects.
- Market Crash: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter from the FDA, the stock price plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, highlighting the severe consequences of information asymmetry.
- Information Gap: The complaint claims that despite explicit warnings from the FDA in 2024 and 2025 about insufficient clinical data, Corcept's management allegedly conveyed an optimistic outlook to investors, resulting in significant financial losses for shareholders.
See More
Corcept Faces Securities Class Action Lawsuit
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: The lawsuit alleges that Corcept and certain executives failed to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA approval for their lead product candidate, relacorilant.
- FDA Response Letter: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding the NDA for relacorilant, stating that additional evidence was needed to assess its effectiveness, which led to a significant loss of investor confidence.
- Stock Price Plunge: Following this announcement, Corcept's stock price plummeted by $35.40, or 50.4%, from a closing price of $70.20 on December 30, 2025, to $34.80 on December 31, 2025, severely impacting investors' financial positions.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Deadline: Investors should note that the lead plaintiff deadline for the Corcept (CORT) class action lawsuit is April 21, 2026, and those who purchased shares between October 31, 2024, and December 30, 2025, may be entitled to compensation.
- No Out-of-Pocket Fees: Investors participating in the class action can do so without any upfront costs, as attorney fees will be covered through a contingency fee arrangement, alleviating financial burdens on investors.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its strong capabilities and successful track record in this field.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials supporting the relacorilant NDA, leading to significant investor losses when the truth about the FDA's concerns was revealed, highlighting uncertainties in the drug approval process.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds shareholders of Corcept Therapeutics that the critical lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their loss claims before this date to protect their rights.
- Loss Scope: The lawsuit pertains to investor losses incurred between October 31, 2024, and December 30, 2025, with allegations that the company failed to disclose significant communications with the FDA, leading shareholders to misunderstand the approval potential of its drug candidate, relacorilant.
- Information Disparity Allegations: The complaint claims that Corcept publicly emphasized the potential approval of relacorilant while failing to disclose management's expectations of failure, creating a
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant due to insufficient evidence of effectiveness, resulting in a 50.42% drop in stock price to $34.80, highlighting serious concerns about the adequacy of its clinical development program.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock price plummeted by $35.40, reflecting a pessimistic market sentiment regarding the company's future prospects and severely undermining investor confidence in its drug development capabilities, which could impact future financing and partnership opportunities.
- Class Action Initiated: Investors have filed a class action lawsuit alleging that Corcept made materially false and misleading statements during the Class Period from October 31, 2024, to December 30, 2025, failing to disclose the FDA's significant concerns about the drug's effectiveness assessment, potentially leading to investor losses.
- Legal Deadline: Investors must file a motion by April 21, 2026, to request appointment as lead plaintiff in this class action, indicating the urgency of the case and its potential implications for affected investors, which may trigger further legal and financial liabilities.
See More
Reminder of Class Action for Corcept Therapeutics Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ:CORT) common stock between October 31, 2024, and December 30, 2025, to apply as lead plaintiffs by April 21, 2026, to participate in the class action and seek compensation.
- No Cost Compensation: Participants can receive compensation through a contingency fee arrangement that requires no out-of-pocket expenses, thereby reducing the financial burden on investors and encouraging more affected shareholders to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that Corcept made false statements regarding the efficacy of relacorilant in key clinical trials, leading investors to face significant risks during the FDA approval process, ultimately resulting in a stock price decline and investor losses.
- Law Firm Advantages: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman law firm reminds Corcept Therapeutics shareholders that April 21, 2026, is the critical deadline to apply as lead plaintiff, urging investors to submit their losses before this date.
- Concealed FDA Warnings: The lawsuit alleges that Corcept failed to disclose significant flaws in its communications with the FDA regarding its lead drug candidate, relacorilant, misleading investors about the drug's approval prospects.
- Market Crash: Following the announcement on December 31, 2025, that Corcept received a Complete Response Letter from the FDA, the stock price plummeted from $70.20 to $34.80, erasing nearly $2.5 billion in market capitalization in a single day, highlighting the severe consequences of information asymmetry.
- Information Gap: The complaint claims that despite explicit warnings from the FDA in 2024 and 2025 about insufficient clinical data, Corcept's management allegedly conveyed an optimistic outlook to investors, resulting in significant financial losses for shareholders.
See More
Corcept Faces Securities Class Action Lawsuit
- Deadline for Lawsuit: ClaimsFiler reminds investors that those who purchased Corcept Therapeutics (Nasdaq: CORT) shares between October 31, 2024, and December 30, 2025, must file lead plaintiff applications by April 21, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: The lawsuit alleges that Corcept and certain executives failed to disclose material information during the class period, violating federal securities laws, which misled investors regarding the likelihood of FDA approval for their lead product candidate, relacorilant.
- FDA Response Letter: On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter regarding the NDA for relacorilant, stating that additional evidence was needed to assess its effectiveness, which led to a significant loss of investor confidence.
- Stock Price Plunge: Following this announcement, Corcept's stock price plummeted by $35.40, or 50.4%, from a closing price of $70.20 on December 30, 2025, to $34.80 on December 31, 2025, severely impacting investors' financial positions.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Litigation Deadline: Investors should note that the lead plaintiff deadline for the Corcept (CORT) class action lawsuit is April 21, 2026, and those who purchased shares between October 31, 2024, and December 30, 2025, may be entitled to compensation.
- No Out-of-Pocket Fees: Investors participating in the class action can do so without any upfront costs, as attorney fees will be covered through a contingency fee arrangement, alleviating financial burdens on investors.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its strong capabilities and successful track record in this field.
- FDA Approval Risks: The lawsuit alleges that Corcept misrepresented the adequacy of clinical trials supporting the relacorilant NDA, leading to significant investor losses when the truth about the FDA's concerns was revealed, highlighting uncertainties in the drug approval process.
See More
Corcept Therapeutics Shareholder Lawsuit Reminder
- Lawsuit Deadline: Hagens Berman reminds shareholders of Corcept Therapeutics that the critical lead plaintiff deadline for the pending securities class action is April 21, 2026, urging investors to submit their loss claims before this date to protect their rights.
- Loss Scope: The lawsuit pertains to investor losses incurred between October 31, 2024, and December 30, 2025, with allegations that the company failed to disclose significant communications with the FDA, leading shareholders to misunderstand the approval potential of its drug candidate, relacorilant.
- Information Disparity Allegations: The complaint claims that Corcept publicly emphasized the potential approval of relacorilant while failing to disclose management's expectations of failure, creating a
See More
Corcept's Drug Application Rejected by FDA, Class Action Filed
- FDA Rejection: On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter (CRL) declining to approve its New Drug Application (NDA) for relacorilant due to insufficient evidence of effectiveness, resulting in a 50.42% drop in stock price to $34.80, highlighting serious concerns about the adequacy of its clinical development program.
- Stock Price Volatility: Following the FDA's rejection, Corcept's stock price plummeted by $35.40, reflecting a pessimistic market sentiment regarding the company's future prospects and severely undermining investor confidence in its drug development capabilities, which could impact future financing and partnership opportunities.
- Class Action Initiated: Investors have filed a class action lawsuit alleging that Corcept made materially false and misleading statements during the Class Period from October 31, 2024, to December 30, 2025, failing to disclose the FDA's significant concerns about the drug's effectiveness assessment, potentially leading to investor losses.
- Legal Deadline: Investors must file a motion by April 21, 2026, to request appointment as lead plaintiff in this class action, indicating the urgency of the case and its potential implications for affected investors, which may trigger further legal and financial liabilities.
See More
